Anita Driessen-Mol1, Maximilian Y Emmert2, Petra E Dijkman3, Laura Frese3, Bart Sanders1, Benedikt Weber4, Nikola Cesarovic5, Michele Sidler6, Jori Leenders1, Rolf Jenni7, Jürg Grünenfelder7, Volkmar Falk7, Frank P T Baaijens1, Simon P Hoerstrup8. 1. Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, the Netherlands. 2. Swiss Center of Regenerative Medicine, University and University Hospital Zürich, Zürich, Switzerland; Center Surgery, Division of Surgical Research, University Hospital Zürich, Zürich, Switzerland; Heart Center Zürich, University Hospital Zürich, Zürich, Switzerland. 3. Swiss Center of Regenerative Medicine, University and University Hospital Zürich, Zürich, Switzerland. 4. Swiss Center of Regenerative Medicine, University and University Hospital Zürich, Zürich, Switzerland; Center Surgery, Division of Surgical Research, University Hospital Zürich, Zürich, Switzerland. 5. Center Surgery, Division of Surgical Research, University Hospital Zürich, Zürich, Switzerland. 6. Center of Applied Biotechnology and Molecular Medicine (CABMM), University of Zürich, Zürich, Switzerland. 7. Heart Center Zürich, University Hospital Zürich, Zürich, Switzerland. 8. Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, the Netherlands; Swiss Center of Regenerative Medicine, University and University Hospital Zürich, Zürich, Switzerland; Center Surgery, Division of Surgical Research, University Hospital Zürich, Zürich, Switzerland; Heart Center Zürich, University Hospital Zürich, Zürich, Switzerland; Center of Applied Biotechnology and Molecular Medicine (CABMM), University of Zürich, Zürich, Switzerland. Electronic address: simon_philipp.hoerstrup@usz.ch.
Abstract
OBJECTIVES: This study sought to evaluate long-term in vivo functionality, host cell repopulation, and remodeling of "off-the-shelf" tissue engineered transcatheter homologous heart valves. BACKGROUND: Transcatheter valve implantation has emerged as a valid alternative to conventional surgery, in particular for elderly high-risk patients. However, currently used bioprosthetic transcatheter valves are prone to progressive dysfunctional degeneration, limiting their use in younger patients. To overcome these limitations, the concept of tissue engineered heart valves with self-repair capacity has been introduced as next-generation technology. METHODS: In vivo functionality, host cell repopulation, and matrix remodeling of homologous transcatheter tissue-engineered heart valves (TEHVs) was evaluated up to 24 weeks as pulmonary valve replacements (transapical access) in sheep (n = 12). As a control, tissue composition and structure were analyzed in identical not implanted TEHVs (n = 5). RESULTS: Transcatheter implantation was successful in all animals. Valve functionality was excellent displaying sufficient leaflet motion and coaptation with only minor paravalvular leakage in some animals. Mild central regurgitation was detected after 8 weeks, increasing to moderate after 24 weeks, correlating to a compromised leaflet coaptation. Mean and peak transvalvular pressure gradients were 4.4 ± 1.6 mm Hg and 9.7 ± 3.0 mm Hg, respectively. Significant matrix remodeling was observed in the entire valve and corresponded with the rate of host cell repopulation. CONCLUSIONS: For the first time, the feasibility and long-term functionality of transcatheter-based homologous off-the-shelf tissue engineered heart valves are demonstrated in a relevant pre-clinical model. Such engineered heart valves may represent an interesting alternative to current prostheses because of their rapid cellular repopulation, tissue remodeling, and therewith self-repair capacity. The concept of homologous off-the-shelf tissue engineered heart valves may therefore substantially simplify previous tissue engineering concepts toward clinical translation.
OBJECTIVES: This study sought to evaluate long-term in vivo functionality, host cell repopulation, and remodeling of "off-the-shelf" tissue engineered transcatheter homologous heart valves. BACKGROUND: Transcatheter valve implantation has emerged as a valid alternative to conventional surgery, in particular for elderly high-risk patients. However, currently used bioprosthetic transcatheter valves are prone to progressive dysfunctional degeneration, limiting their use in younger patients. To overcome these limitations, the concept of tissue engineered heart valves with self-repair capacity has been introduced as next-generation technology. METHODS: In vivo functionality, host cell repopulation, and matrix remodeling of homologous transcatheter tissue-engineered heart valves (TEHVs) was evaluated up to 24 weeks as pulmonary valve replacements (transapical access) in sheep (n = 12). As a control, tissue composition and structure were analyzed in identical not implanted TEHVs (n = 5). RESULTS: Transcatheter implantation was successful in all animals. Valve functionality was excellent displaying sufficient leaflet motion and coaptation with only minor paravalvular leakage in some animals. Mild central regurgitation was detected after 8 weeks, increasing to moderate after 24 weeks, correlating to a compromised leaflet coaptation. Mean and peak transvalvular pressure gradients were 4.4 ± 1.6 mm Hg and 9.7 ± 3.0 mm Hg, respectively. Significant matrix remodeling was observed in the entire valve and corresponded with the rate of host cell repopulation. CONCLUSIONS: For the first time, the feasibility and long-term functionality of transcatheter-based homologous off-the-shelf tissue engineered heart valves are demonstrated in a relevant pre-clinical model. Such engineered heart valves may represent an interesting alternative to current prostheses because of their rapid cellular repopulation, tissue remodeling, and therewith self-repair capacity. The concept of homologous off-the-shelf tissue engineered heart valves may therefore substantially simplify previous tissue engineering concepts toward clinical translation.
Authors: Petra E Dijkman; Emanuela S Fioretta; Laura Frese; Francesco S Pasqualini; Simon P Hoerstrup Journal: Transfus Med Hemother Date: 2016-07-26 Impact factor: 3.747
Authors: M A J van Kelle; P J A Oomen; W J T Janssen-van den Broek; R G P Lopata; S Loerakker; C V C Bouten Journal: J R Soc Interface Date: 2018-11-14 Impact factor: 4.118
Authors: Andrew K Capulli; Maximillian Y Emmert; Francesco S Pasqualini; Debora Kehl; Etem Caliskan; Johan U Lind; Sean P Sheehy; Sung Jin Park; Seungkuk Ahn; Benedikt Weber; Josue A Goss; Simon P Hoerstrup; Kevin Kit Parker Journal: Biomaterials Date: 2017-04-18 Impact factor: 12.479
Authors: Sarah E Motta; Emanuela S Fioretta; Petra E Dijkman; Valentina Lintas; Luc Behr; Simon P Hoerstrup; Maximilian Y Emmert Journal: J Cardiovasc Transl Res Date: 2018-03-20 Impact factor: 4.132
Authors: Iyore A James; Tai Yi; Shuhei Tara; Cameron A Best; Alexander J Stuber; Kejal V Shah; Blair F Austin; Tadahisa Sugiura; Yong-Ung Lee; Joy Lincoln; Aaron J Trask; Toshiharu Shinoka; Christopher K Breuer Journal: Tissue Eng Part C Methods Date: 2015-05-29 Impact factor: 3.056
Authors: Aline L Y Nachlas; Siyi Li; Benjamin W Streeter; Kenneth J De Jesus Morales; Fatiesa Sulejmani; David Immanuel Madukauwa-David; Donald Bejleri; Wei Sun; Ajit P Yoganathan; Michael E Davis Journal: Biomaterials Date: 2020-02-12 Impact factor: 12.479